DROPERIDOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H22FN3O2
Molecular Weight	379.4274
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4

InChI

InChIKey=RMEDXOLNCUSCGS-UHFFFAOYSA-N

InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)

HIDE SMILES / InChI

Molecular Formula	C22H22FN3O2
Molecular Weight	379.4274
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/droperidol.html

Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00450	Antagonist 2849
Alpha-1a adrenergic receptor 67 Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00450	Antagonist 2849
HERG 99 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12190308	Inhibitor 8504	32.2 nM [IC50]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2879412	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nausea and vomiting associated with surgical and diagnostic procedures 2 Sources: https://www.drugs.com/pro/droperidol.html	Secondary		Approved 8583	INAPSINE Approved Use Droperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Launch Date 1970

C_max

Value	Dose	Co-administered	Analyte	Population
26.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
40 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/	0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered:		DROPERIDOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985	unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985	Disc. AE: QT interval prolonged... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x https://pubmed.ncbi.nlm.nih.gov/337985
8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051	Other AEs: Asthenia, Chills... Other AEs: Asthenia (24.6%) Chills (3.3%) Anorexia (3.3%) Akathisia (16.4%) Anxiety (27.9%) Confusion (3.3%) Dizziness (9.8%) Dry mouth (9.8%) Nervousness (4.9%) Paresthesia (3.3%) Somnolence (24.6%) Tremor (1.6%) Pharyngitis (4.9%) Rhinitis (4.9%) Sweaty (8.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/25416184 https://pubmed.ncbi.nlm.nih.gov/12552051
2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x	Disc. AE: Torsades de pointes... AEs leading to discontinuation/dose reduction: Torsades de pointes Sources: https://pubmed.ncbi.nlm.nih.gov/15320756 https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP1 116	CYP3A5 446

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
MRP1 232	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/dmd/early/2018/09/19/dmd.118.081612.full.pdf Page: 19.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2803%2990413-9	major
CYP3A5 446	substrate 4014 Sources: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2803%2990413-9	major

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/18349188/

Sourcing

Vendor/Aggregator	ID	URL
PubChem	9956314	https://pubchem.ncbi.nlm.nih.gov/compound/9956314
SureChEMBL	SCHEMBL8356614	https://www.surechembl.org/chemical/SCHEMBL8356614
Wikidata	Q27236492

PubMed

Title	Date	PubMed
Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients.	2002-10	12378031
Droperidol: a cost-effective antiemetic for over thirty years.	2002-10	12351246
Low-dose droperidol.	2002-09-03	12240805
Continuum of care: stabilizing the acutely agitated patient.	2002-09-01	12227082
Effects of anesthesia on efferent-mediated adaptation of the DPOAE.	2002-09	12382109
The addition of antiemetics to the morphine solution in patient controlled analgesia syringes used by children after an appendicectomy does not reduce the incidence of postoperative nausea and vomiting.	2002-09	12358655
P6 acupoint injections are as effective as droperidol in controlling early postoperative nausea and vomiting in children.	2002-08	12151925
Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics.	2002-07-13	12113564
Dolasetron decreases postoperative nausea and vomiting after breast surgery.	2002-07-09	12100113
The rise and withdrawal of droperidol.	2002-07	12226953
Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery.	2002-07	12167446
The FDA droperidol warning: is it justified?	2002-07	12131147
Droperidol "box warning" warrants scrutiny.	2002-07	12131146
FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified?	2002-07	12131145
Derivative spectrophotometric determination of droperidol in presence of parabens.	2002-06-20	12062683
[Effects of preincisional epidural administration of lidocaine and fentanyl on postoperative pain management following hysterectomy].	2002-06-10	12126546
Arrhythmias from droperidol?	2002-06-10	12058151
Evaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure.	2002-06	12173200
Gateways to Clinical Trials. June 2002.	2002-06	12168506
Four-step local anesthesia and sedation for thoracoscopic diagnosis and management of pleural diseases.	2002-06	12065373
Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial.	2002-06	12045085
Droperidol--behind the black box warning.	2002-06	12045077
Rapid tranquillisation: time for a reappraisal of options for parenteral therapy.	2002-06	12042225
LC determination and degradation study of droperidol.	2002-05-15	12008124
Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy.	2002-05	12075944
Using imprecise probabilities to address the questions of inference and decision in randomized clinical trials.	2002-05	12060416
Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery.	2002-05	12027845
Psychotropic drugs and the ECG: focus on the QTc interval.	2002-05	11996627
Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery.	2002-05	11981150
Droperidol: cardiovascular toxicity and deaths.	2002-04-02	11949994
A placebo-controlled, randomized trial of droperidol versus metoclopramide for outpatients undergoing gynecological laparoscopy under conscious sedation.	2002-04	12118494
Use of sevoflurane during cardiopulmonary bypass decreases incidence of awareness.	2002-04	12074418
Droperidol inhibits GABA(A) and neuronal nicotinic receptor activation.	2002-04	11964609
Black-box warning for droperidol surprises pharmacists.	2002-03-15	11908241
Continuous epidural, not intravenous, droperidol inhibits pruritus, nausea, and vomiting during epidural morphine analgesia.	2002-03	11943525
Superior prolonged antiemetic prophylaxis with a four-drug multimodal regimen - comparison with propofol or placebo.	2002-03	11939911
Inapsine. Weighing the risk of fatal arrhythmias.	2002-03	11902037
Treatment patterns of isolated benign headache in US emergency departments.	2002-03	11867972
[Continuous epidural administration of droperidol to prevent postoperative nausea and vomiting].	2002-02	11889776
Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin.	2002-01-21	11870505
[Prophylaxis of Postoperative Nausea and Vomiting FollowingGynaecological Laparoscopy].	2002-01	11845375
[Droperidol causes multifocal ventricular dysrhythmias].	2002-01	11840665
A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache.	2002-01	11781912
Premedication, preparation, and surveillance.	2002-01	11778125
Effects of sevoflurane on electrocorticography in patients with intractable temporal lobe epilepsy.	2002-01	11773826
The black box warning.	2002	12380043
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.	2002	12109926
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study.	2002	11860610
Warnings strengthened on tranquilizer inapsine (Droperidol).	2001-12-18	11748130
Evaluation of droperidol in the acutely agitated child or adolescent.	2001-11	11761643

Patents

Sample Use Guides

In Vivo Use Guide

Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely. Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.

Route of Administration: Intravenous

In Vitro Use Guide

Droperidol (10(-7) M) caused vasodilator effect (approximately 20% of vasorelaxation compared with maximal vasorelaxation induced by papaverine [3 x 10(-4) M] in rat vascular smooth muscle cells.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:55:21 GMT 2025` Edited by `admin` on `Wed Apr 02 07:55:21 GMT 2025`
Record UNII	O9U0F09D5X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DROPERIDOL

Official Name

English

DROLEPTAN

Preferred Name

English

R-4749

Code

English

NSC-169874

Code

English

DROPERIDOL [VANDF]

Common Name

English

DROPERIDOL [ORANGE BOOK]

Common Name

English

MCN-JR-4749

Code

English

DROPERIDOL [GREEN BOOK]

Common Name

English

DROPERIDOL [USP-RS]

Common Name

English

INNOVAR COMPONENT DROPERIDOL

Common Name

English

DROPERIDOL [MART.]

Common Name

English

DROPERIDOL [USP MONOGRAPH]

Common Name

English

Droperidol [WHO-DD]

Common Name

English

1-(1-(3-(P-FLUOROBENZOYL)PROPYL)-1,2,3,6-TETRAHYDRO-4-PYRIDYL)-2-BENZIMIDAZOLINONE

Common Name

English

DROPERIDOL [HSDB]

Common Name

English

DROPERIDOL [USAN]

Common Name

English

DROPERIDOL [JAN]

Common Name

English

2H-BENZIMIDAZOL-2-ONE, 1-(1-(4-(4-FLUOROPHENYL)-4-OXOBUTYL)-1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1,3-DIHYDRO-

Systematic Name

English

droperidol [INN]

Common Name

English

DROPERIDOL [MI]

Common Name

English

INAPSINE

Brand Name

English

DROPERIDOL [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N05AD08